The out-sourced drug development company, RxCelerate Ltd, completed the acquisition of Cambridge-based specialist bioanalytical contract research organisation, Total Scientific Ltd.
Total Scientific was founded in 2006, on the Babraham Research Campus (UK), and specialises in measuring complex drugs and proteins in biological samples, compliant with Good Laboratory Practice (GLP).
RxCelerate, which has offices in Cambridge, Massachusetts, USA, and Cambridge, UK, provides bespoke drug development services to clients ranging from virtual biotech companies to global pharmaceutical giants. Its unique model is built around out-sourcing drug development expertise rather than practical experimental work, allowing RxCelerate to guide projects from discovery through to the clinic as efficiently as possible.
RxCelerate offers a wide range of services. The biology team specializes in in vivo pharmacology, offering proprietary models of wide range of human diseases, as well as complex cell-based assays. The chemistry team provides medicinal chemistry, including in silico screening, and synthesis that integrates seamlessly with the in vitro testing capability. A dedicated team designs the optimum discovery or development strategy for each project, as well as integrated program management. By working closely together, these teams can deliver pharma-grade drug product candidates at a fraction of the cost of traditional approaches.